Pfizer has appointed a chief digital officer because of the growing importance of digital technology in its R&D and business process, as part of a boardroom shake-up.
Pfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and business process, as part of a boardroom shake-up.
Pfizer’s Mylotarg has been approved by the English and Scottish NHS cost watchdogs as a restricted use treatment for a certain type of acute myeloid leukaemia (AML).
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.
Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.